We are a Nanobody Development Platform for Human and Animal Pharmaceutical Industry.
Our technological proposal is based on a versatile nanobody development platform that enables us to generate and rationally select the best candidates for each application, allowing us to deliver innovative and effective solutions to address unmet needs in various fields.
SMALL: 10 times smaller than conventional antibodies. High penetrability.
ROBUST: 1 single protein domain of the Ig type, with stabilized structure.
STABLE: Resistant to wide ranges of pH, temperature, and ionic strength. Soluble at high concentrations.
LOW COST: Production in prokaryotic or yeast systems with high yields.
VERSATILE: Wide range of therapeutic applications and administration routes.
SIMPLE LOGISTICS: Does not require cold chain.
MBA. Nicolás Galmarini
Nicolás Galmarini has a Bachelor’s degree in Economics from UdelaR and an MBA from the Universidad Austral de Argentina. He has over 15 years of experience in the pharmaceutical industry. He also serves as an advisor in the region for the development of pharmaceutical projects and is an entrepreneur in businesses related to the human and veterinary pharmaceutical industry.
PhD. Lucía Vanrell
Lucía Vanrell is a biochemist who graduated from the University of the Republic (UdelaR) and completed her PhD at the Center for Applied Medical Research (CIMA) at the University of Navarra.
With over 15 years of experience in immunotherapy research and more than 10 years specializing in nanobodies, she has collaborated with high-level international scientific groups around the world. She has published numerous papers in high-impact journals and is a co-inventor of 3 international patent applications, 1 of which has been granted in the US. She currently works as a professor and researcher at Universidad ORT-Uruguay and is a member of the National System of Researchers at Level I.
Eng. Laura Salaberry
PhD. Cecilia Ruibal
MSc. Martina Steglich